Kathy S. Albain

Also affiliated with Loyola University Chicago

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 31 papers. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Journal of Clinical Oncology(2020)10.1200/jco.19.01866

N/A

3.5DataRank · unranked

102 citations

Robert J. Gray, Joseph A. Sparano, Timothy J. Whelan, Sofia F. Garcia, Betina R. Yanez +14 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7062

N/A

0.883DataRank · unranked

27 citations

Gary Zirpoli, William E. Barlow, G. Thomas Budd, Bryan McKiver, Lajos Pusztai +10 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

Biomarkers(2023)10.1080/1354750x.2023.2168063

N/A

0.587DataRank · unranked

12 citations

Adrian Nordmark, Amy Williams, Costanza Paoletti, William E. Barlow, Erin F. Cobain +11 more

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae314

N/A

0.443DataRank · unranked

10 citations

William E. Barlow, Julie R. Gralow, Funda Meric‐Bernstam, Kathy S. Albain, Daniel F. Hayes +19 more

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221

Research Square(2023)10.21203/rs.3.rs-3242513/v1

N/A

0.104DataRank · unranked

1 citations

Gary Zirpoli, G. Thomas Budd, William E. Barlow, Lajos Pusztai, Gabriel N. Hortobágyi +8 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.02.009

N/A

0DataRank · unranked

26 citations

Jieling Miao, Mihaela Cristea, Allen Chen, Jacob Sands, Roy H. Decker +13 more

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1562

N/A

0DataRank · unranked

19 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer

The Annals of Thoracic Surgery(2022)10.1016/j.athoracsur.2022.11.021

N/A

0DataRank · unranked

15 citations

Douglas E. Wood, Wickii T. Vigneswaran, Amit Goyal, Cheryl Czerlanis, Shanda H. Blackmon +5 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0DataRank · unranked

175 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

Data from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches

(2023)10.1158/0008-5472.c.6497490

N/A

0DataRank · unranked

0 citations

Haixi Miao, Gwendolyn D'Souza, Clodia Osipo, Jieun Yun, Huiping Zhao +19 more

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

(2023)10.1158/1078-0432.c.6530384.v1

N/A

0DataRank · unranked

0 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

(2023)10.1158/1078-0432.c.6530384

N/A

0DataRank · unranked

0 citations

William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow +9 more

Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1076

N/A

0DataRank · unranked

0 citations

William E. Barlow, Costanza Paoletti, Mattias Bergqvist, Amy Williams, Hanna Ritzén +11 more

Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04680-6

N/A

0DataRank · unranked

1 citations

Gary Zirpoli, G. Thomas Budd, William E. Barlow, Lajos Pusztai, Gabriel N. Hortobágyi +8 more

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial

UNC Libraries(2025)10.17615/dgtt-ap31

N/A

0DataRank · unranked

0 citations

Julie R. Gralow, Edith Perez, Kevin Kalinsky, Gabriel N. Hortobágyi, Nancy U. Lin +19 more

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa148

N/A

0DataRank · unranked

115 citations

Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer +23 more

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2019.5559

N/A

0DataRank · unranked

78 citations

William E. Barlow, Reshma Jagsi, Thomas A. Buchholz, Steven Shak, Frederick L. Baehner +13 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95

N/A

0DataRank · unranked

1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)

UNC Libraries(2020)10.17615/e33z-ag80

N/A

0DataRank · unranked

0 citations

Harold J. Burstein, Lisa A. Carey, Antonio C. Wolff, Sara M. Tolaney, P. Kelly Marcom +15 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0DataRank · unranked

447 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0DataRank · unranked

335 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0DataRank · unranked

73 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more